Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Next Previous
X
Search
Trial Profile

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Mast Cell Leukemia; Systemic mastocytosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHFINDER
  • Sponsors Blueprint Medicines

    • Most Recent Events

    • 30 May 2024 According to a Blueprint Medicines media release, data from this trial will be presented at European Hematology Association 2024 (EHA24) Hybrid Congress
    • 01 Aug 2023 Planned End Date changed from 1 Jan 2026 to 31 Jan 2026.
    • 01 Aug 2023 Planned primary completion date changed from 1 Jan 2026 to 31 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top